
So-Ryoung Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5435368/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding. Cardiovascular Drugs and Therapy, 2022, 36, 679-689.	1.3	10
2	Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. PLoS ONE, 2022, 17, e0264538.	1.1	5
3	Non-alcoholic Fatty Liver Disease and the Risk of Incident Atrial Fibrillation in Young Adults: A Nationwide Population-Based Cohort Study. Frontiers in Cardiovascular Medicine, 2022, 9, 832023.	1.1	7
4	Novel presentation of SCN5A nonsense mutation as SCN5A overlap syndrome. HeartRhythm Case Reports, 2022, 8, 209-213.	0.2	0
5	Low Risk of Dementia in Patients With Newly Diagnosed Atrial Fibrillation and a Clustering of Healthy Lifestyle Behaviors: A Nationwide Populationâ€Based Cohort Study. Journal of the American Heart Association, 2022, 11, e023739.	1.6	11
6	Clinical outcomes in patients with persistent atrial fibrillation after technologic advances including contact force-guided and ablation index-guided ablation. International Journal of Arrhythmia, 2022, 23, .	0.3	1
7	Comparison Between the 24-hour Holter Test and 72-hour Single-Lead Electrocardiogram Monitoring With an Adhesive Patch-Type Device for Atrial Fibrillation Detection: Prospective Cohort Study. Journal of Medical Internet Research, 2022, 24, e37970.	2.1	10

8 System of integrating biosignals during hemodialysis: the CONTINUAL (Continuous mOnitoriNg viTal) Tj ETQq0 0 0 0 gBT /Overlock 10 Tf

9	Risk of Dementia After Smoking Cessation in Patients With Newly Diagnosed Atrial Fibrillation. JAMA Network Open, 2022, 5, e2217132.	2.8	8
10	Nonvitamin K Antagonist Oral Anticoagulants in Patients with Extreme Body Weights: One Size Fits All?. Thrombosis and Haemostasis, 2021, 121, 115-117.	1.8	0
11	Impact of the Combinations of Allergic Diseases on Myocardial Infarction and Mortality. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 872-880.e4.	2.0	12
12	Effect of alcohol consumption on the risk of adverse events in atrial fibrillation: from the COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) registry. Europace, 2021, 23, 548-556.	0.7	14
13	Adherence to dabigatran and the influence of dabigatran-induced gastrointestinal discomfort in the real-world practice. International Journal of Cardiology, 2021, 323, 77-82.	0.8	4
14	Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 415-423.	1.4	24
15	Cumulative burden of metabolic syndrome and its components on the risk of atrial fibrillation: a nationwide population-based study. Cardiovascular Diabetology, 2021, 20, 20.	2.7	22
16	Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Prior Gastrointestinal Bleeding. Stroke, 2021, 52, 511-520.	1.0	19
17	Lifestyle is associated with atrial fibrillation development in patients with type 2 diabetes mellitus. Scientific Reports, 2021, 11, 4676.	1.6	13
18	Body Mass Index and Clinical Outcomes in Asian Patients With Atrial Fibrillation Receiving Oral Anticoagulation. Stroke, 2021, 52, 521-530.	1.0	18

#	Article	IF	CITATIONS
19	Nonalcoholic fatty liver disease and the risk of atrial fibrillation stratified by body mass index: a nationwide population-based study. Scientific Reports, 2021, 11, 3737.	1.6	17
20	Stroke and systemic embolism in patients with atrial fibrillation and heart failure according to heart failure failure type. ESC Heart Failure, 2021, 8, 1582-1589.	1.4	17
21	Do we need more evidence for oral anticoagulants in everyday practice?. Heart, 2021, 107, 943-944.	1.2	1
22	Hypertension Burden and the Risk of New-Onset Atrial Fibrillation. Hypertension, 2021, 77, 919-928.	1.3	22
23	Longitudinal Patterns in Antithrombotic Therapy in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention in the Non-Vitamin K Oral Anticoagulant Era: A Nationwide Population-Based Study. Journal of Clinical Medicine, 2021, 10, 1505.	1.0	4
24	Alcohol Abstinence and the Risk of Atrial Fibrillation in Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Nationwide Population-Based Study. Diabetes Care, 2021, 44, 1393-1401.	4.3	21
25	Validation of Adhesive Single-Lead ECG Device Compared with Holter Monitoring among Non-Atrial Fibrillation Patients. Sensors, 2021, 21, 3122.	2.1	20
26	Predictors of ischemic stroke for low-risk patients with atrial fibrillation: A matched case-control study. Heart Rhythm, 2021, 18, 702-708.	0.3	7
27	Smoking Cessation after Diagnosis of New-Onset Atrial Fibrillation and the Risk of Stroke and Death. Journal of Clinical Medicine, 2021, 10, 2238.	1.0	13
28	Association between exercise habits and stroke, heart failure, and mortality in Korean patients with incident atrial fibrillation: A nationwide population-based cohort study. PLoS Medicine, 2021, 18, e1003659.	3.9	25
29	Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study. European Heart Journal, 2021, 42, 4759-4768.	1.0	36
30	Risk of Atrial Fibrillation According to Cancer Type. JACC: CardioOncology, 2021, 3, 221-232.	1.7	60
31	Exercise and the Risk of Dementia in Patients with Newly Diagnosed Atrial Fibrillation: A Nationwide Population-Based Study. Journal of Clinical Medicine, 2021, 10, 3126.	1.0	15
32	Hypertension control and end-stage renal disease in atrial fibrillation: a nationwide population-based cohort study. Clinical Research in Cardiology, 2021, , 1.	1.5	2
33	Acute and longâ€term efficacy of ablation indexâ€guided higher power shorter duration ablation in patients with atrial fibrillation: A prospective registry. Journal of Arrhythmia, 2021, 37, 1250-1259.	0.5	6
34	Increased Risk of Atrial Fibrillation in Patients with Atopic Triad: A Nationwide Population-Based Study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3422-3430.e5.	2.0	6
35	Comparing Warfarin and 4 Direct Oral Anticoagulants for the Risk of Dementia in Patients With Atrial Fibrillation. Stroke, 2021, 52, 3459-3468.	1.0	32
36	Risk of Atrial Fibrillation in Young Adults With Isolated Diastolic, Isolated Systolic, and Systolic-Diastolic Hypertension. Hypertension, 2021, 78, 1248-1258.	1.3	7

#	Article	IF	CITATIONS
37	Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Korean Circulation Journal, 2021, 51, 409.	0.7	10
38	Catheter ablation of atrial fibrillation in Korea: results from the Korean Heart Rhythm Society Ablation Registry for Atrial Fibrillation (KARA). International Journal of Arrhythmia, 2021, 22, .	0.3	1
39	Response to Comment on Choi et al. Alcohol Abstinence and the Risk of Atrial Fibrillation in Patients With Newly Diagnosed Type 2 Diabetes Mellitus: a Nationwide Population-Based Study. Diabetes Care 2021;44:1393–1401. Diabetes Care, 2021, 44, e199-e199.	4.3	0
40	Clinical impact of left atrial enlargement in Korean patients with atrial fibrillation. Scientific Reports, 2021, 11, 23808.	1.6	7
41	Bodyweight fluctuation is associated with increased risk of incident atrial fibrillation. Heart Rhythm, 2020, 17, 365-371.	0.3	32
42	Effect of the variability of blood pressure, glucose level, total cholesterol level, and body mass index on the risk of atrial fibrillation in a healthy population. Heart Rhythm, 2020, 17, 12-19.	0.3	22
43	Blood Pressure Variability and Incidence of New-Onset Atrial Fibrillation. Hypertension, 2020, 75, 309-315.	1.3	45
44	Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage. Stroke, 2020, 51, 416-423.	1.0	42
45	Temporal trends of catheter ablation for patients with atrial fibrillation: A Korean nationwide populationâ€based study. Journal of Cardiovascular Electrophysiology, 2020, 31, 2616-2625.	0.8	6
46	Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study. American Heart Journal, 2020, 229, 81-91.	1.2	11
47	Comparative clinical outcomes of dronedarone and sotalol in Asian patients with atrial fibrillation: a nationwide cohort study. Scientific Reports, 2020, 10, 16102.	1.6	3
48	Relationship between dominant frequency, organization index, and left atrial size in patients with atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2020, 31, 3159-3165.	0.8	2
49	Association between clustering of unhealthy lifestyle factors and risk of new-onset atrial fibrillation: a nationwide population-based study. Scientific Reports, 2020, 10, 19224.	1.6	33
50	Temporal Trends of Emergency Department Visits of Patients with Atrial Fibrillation: A Nationwide Population-Based Study. Journal of Clinical Medicine, 2020, 9, 1485.	1.0	10
51	Response by Lee et al to Letter Regarding Article, "Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage― Stroke, 2020, 51, e112.	1.0	0
52	High variability in bodyweight is associated with an increased risk of atrial fibrillation in patients with type 2 diabetes mellitus: a nationwide cohort study. Cardiovascular Diabetology, 2020, 19, 78.	2.7	20
53	Effectiveness and Safety of Direct Oral Anticoagulants in Relation to Temporal Changes in Their Use. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e005894.	0.9	17
54	Impact of Hemoglobin Levels and Their Dynamic Changes on the Risk of Atrial Fibrillation: A Nationwide Population-Based Study. Scientific Reports, 2020, 10, 6762.	1.6	17

#	Article	IF	CITATIONS
55	Outcomes in relation to antithrombotic therapy among patients with atrial fibrillation after percutaneous coronary intervention. PLoS ONE, 2020, 15, e0240161.	1.1	2
56	Dose Selection of Non-Vitamin K Antagonist Oral Anticoagulants in Korean Patients with Non-Valvular Atrial Fibrillation. Cardiovascular Prevention and Pharmacotherapy, 2020, 2, 1.	0.0	0
57	Is Lighter Intensity of Warfarin Therapy Enough for Korean Patients with Non-Valvular Atrial Fibrillation?. Korean Circulation Journal, 2020, 50, 176.	0.7	0
58	DOACs in Patients With Atrial Fibrillation and Liver Disease. Journal of the American College of Cardiology, 2019, 74, 190-192.	1.2	2
59	Increased risk of atrial fibrillation in patients with Behçet's disease: A nationwide population-based study. International Journal of Cardiology, 2019, 292, 106-111.	0.8	8
60	Direct Oral Anticoagulants in PatientsÂWith Atrial Fibrillation andÂLiverÂDisease. Journal of the American College of Cardiology, 2019, 73, 3295-3308.	1.2	95
61	Risk of Atrial Fibrillation in Relation to the Time Course of Type 2 Diabetes Mellitus and Fasting Blood Glucose. American Journal of Cardiology, 2019, 124, 1881-1888.	0.7	10
62	Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease. Journal of Clinical Medicine, 2019, 8, 1624.	1.0	11
63	Extensive left atrial ablation was associated with exacerbation of left atrial stiffness and dyspnea. Journal of Cardiovascular Electrophysiology, 2019, 30, 2782-2789.	0.8	5
64	Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation. Stroke, 2019, 50, 2245-2249.	1.0	73
65	Meta-Analysis of Oral Anticoagulant Monotherapy as an Antithrombotic Strategy in Patients With Stable Coronary Artery Disease and Nonvalvular Atrial Fibrillation. American Journal of Cardiology, 2019, 124, 879-885.	0.7	29
66	Visit-to-visit variability of metabolic parameters and risk of heart failure: A nationwide population-based study. International Journal of Cardiology, 2019, 293, 153-158.	0.8	25
67	Efficacy of the optimal ablation index–targeted strategy for pulmonary vein isolation in patients with atrial fibrillation: the OPTIMUM study results. Journal of Interventional Cardiac Electrophysiology, 2019, 55, 171-181.	0.6	25
68	Non–Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function. Stroke, 2019, 50, 1480-1489.	1.0	19
69	Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation. Scientific Reports, 2019, 9, 6690.	1.6	15
70	Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation. Yonsei Medical Journal, 2019, 60, 277.	0.9	56
71	Optimal Rivaroxaban Dose in Asian Patients With Atrial Fibrillation and Normal or Mildly Impaired Renal Function. Stroke, 2019, 50, 1140-1148.	1.0	39
72	Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention During 2-Year Follow-Up, from a Nationwide Population Study. American Journal of Cardiology, 2019, 123, 1921-1926.	0.7	7

#	Article	IF	CITATIONS
73	Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation andÂLowÂBodyÂWeight. Journal of the American College of Cardiology, 2019, 73, 919-931.	1.2	72
74	Validation of diagnostic codes of major clinical outcomes in a National Health Insurance database. International Journal of Arrhythmia, 2019, 20, .	0.3	73
75	Association between Atrial Fibrillation, Myocardial Infarction, Heart Failure and Mortality in Patients with Nontuberculous Mycobacterial Infection: a nationwide population-based study. Scientific Reports, 2019, 9, 15503.	1.6	4
76	Effectiveness and Safety of Direct Oral Anticoagulant for Secondary Prevention in Asians with Atrial Fibrillation. Journal of Clinical Medicine, 2019, 8, 2228.	1.0	24
77	Fluctuating renal function and the risk of incident atrial fibrillation: a nationwide population-based study. Scientific Reports, 2019, 9, 18055.	1.6	4
78	Association between lower urinary tract symptoms and cardiovascular risk scores in ostensibly healthy women. BJU International, 2019, 123, 669-675.	1.3	4
79	Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study. PLoS ONE, 2019, 14, e0209593.	1.1	22
80	Re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol 2018;74:501–9. European Urology, 2019, 75, e57-e58.	0.9	0
81	Ankylosing spondylitis: A novel risk factor for atrial fibrillation — A nationwide population-based study. International Journal of Cardiology, 2019, 275, 77-82.	0.8	31
82	Increased risk of atrial fibrillation in patients with inflammatory bowel disease: A nationwide population-based study. World Journal of Gastroenterology, 2019, 25, 2788-2798.	1.4	41
83	Temporal Trends of Cardiac Implantable Electronic Device Implantations: a Nationwide Population-based Study. Korean Circulation Journal, 2019, 49, 841.	0.7	32
84	Short stature is associated with the development of lower limb ischaemia during extracorporeal life support. Perfusion (United Kingdom), 2018, 33, 383-389.	0.5	7
85	Association between adult height, myocardial infarction, heart failure, stroke and death: a Korean nationwide population-based study. International Journal of Epidemiology, 2018, 47, 289-298.	0.9	45
86	Atrial Innervation Patterns of Intrinsic Cardiac Autonomic Nerves. Journal of Korean Medical Science, 2018, 33, e253.	1.1	3
87	2018 Korean Guideline of Atrial Fibrillation Management. Korean Circulation Journal, 2018, 48, 1033.	0.7	108
88	Mortality and causes of death in patients with atrial fibrillation: A nationwide population-based study. PLoS ONE, 2018, 13, e0209687.	1.1	108
89	Increased Risk of Atrial Fibrillation in the Early Period after Herpes Zoster Infection: a Nationwide Population-based Case-control Study. Journal of Korean Medical Science, 2018, 33, e160.	1.1	8
90	Prevalence of Non-valvular Atrial Fibrillation Based on Geographical Distribution and Socioeconomic Status in the Entire Korean Population. Korean Circulation Journal, 2018, 48, 622.	0.7	28

#	Article	IF	CITATIONS
91	Stroke Prevention in Atrial Fibrillation: Focus on Asian Patients. Korean Circulation Journal, 2018, 48, 665.	0.7	44
92	Edoxaban in Asian Patients With AtrialÂFibrillation. Journal of the American College of Cardiology, 2018, 72, 838-853.	1.2	93
93	Discrimination of stress (Takotsubo) cardiomyopathy from acute coronary syndrome with clinical risk factors and coronary evaluation in real-world clinical practice. International Journal of Cardiology, 2017, 235, 154-161.	0.8	11
94	Trends in the incidence and prevalence of atrial fibrillation and estimated thromboembolic risk using the CHA2DS2-VASc score in the entire Korean population. International Journal of Cardiology, 2017, 236, 226-231.	0.8	150
95	Cirrhosis is a risk factor for atrial fibrillation: A nationwide, populationâ€based study. Liver International, 2017, 37, 1660-1667.	1.9	54
96	Atrial fibrillation risk in metabolically healthy obesity: A nationwide population-based study. International Journal of Cardiology, 2017, 240, 221-227.	0.8	59
97	Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants. Heart Rhythm, 2017, 14, 501-507.	0.3	62
98	Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation. Stroke, 2017, 48, 3040-3048.	1.0	117
99	Increased Risk of Atrial Fibrillation and Thromboembolism in Patients with Severe Psoriasis: a Nationwide Population-based Study. Scientific Reports, 2017, 7, 9973.	1.6	37
100	Association between Î ³ -glutamyltransferase level and incidence of atrial fibrillation: A nationwide population-based study. International Journal of Cardiology, 2017, 245, 149-155.	0.8	13
101	Proteinuria Detected by Urine Dipstick Test as a Risk Factor for Atrial Fibrillation: A Nationwide Population-Based Study. Scientific Reports, 2017, 7, 6324.	1.6	22
102	Predictors of candesartan's effect on vascular reactivity in patients with coronary artery disease. Cardiovascular Therapeutics, 2017, 35, e12291.	1.1	4
103	Risk of Ischemic Stroke in Patients With Non-Valvular Atrial Fibrillation Not Receiving Oral Anticoagulants ― Korean Nationwide Population-Based Study ―. Circulation Journal, 2017, 81, 1158-1164.	0.7	38
104	Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide population-based study. PLoS ONE, 2017, 12, e0189495.	1.1	71
105	Early Parasympathetic Reinnervation Is Not Related to Reconnection of Major Branches of the Vagus Nerve after Heart Transplantation. Korean Circulation Journal, 2016, 46, 197.	0.7	13
106	Evaluation of the association between diabetic retinopathy and the incidence of atrial fibrillation: A nationwide population-based study. International Journal of Cardiology, 2016, 223, 953-957.	0.8	62
107	Underweight is a risk factor for atrial fibrillation: A nationwide population-based study. International Journal of Cardiology, 2016, 215, 449-456.	0.8	96
108	Left atrial septal ostium of the coronary sinus. Heart Rhythm, 2016, 13, 628-629.	0.3	0

#	Article	IF	CITATIONS
109	Prognostic Implication of QRS Variability during Hospitalization in Patients with Acute Decompensated Heart Failure. Korean Circulation Journal, 2014, 44, 22.	0.7	Ο
110	Increased prevalence of metabolic syndrome among hypertensive population. International Journal of Cardiology, 2013, 166, 633-639.	0.8	25
111	Efficacy and Safety of Oral Anticoagulants for Atrial Fibrillation Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	12